Skip to main navigation Skip to search Skip to main content

Breastfeeding During Maternal Nadolol Therapy for Long QT Syndrome: Five-Month Infant Follow-Up

  • Romane Freppel*
  • , Louise Gaboriau
  • , Beatrice Mestdagh
  • , Louise Ghesquière
  • , Luisa Marsili
  • , Benjamin Hennart
  • , Marjorie Richardson
  • , Sophie Gautier
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Nadolol is the preferred beta-blocker for prophylactic therapy in congenital long QT syndrome (LQTS), but data on infant exposure during breastfeeding are scarce. We describe a 34-year-old woman with LQTS type 1, stabilized on nadolol 80 mg/day, who chose to breastfeed her healthy full-term infant. An individualized follow-up plan was developed by the multidisciplinary pregnancy heart team at Lille University Hospital, including serial maternal and infant nadolol plasma measurements, ECG, growth and clinical assessments. Maternal and infant plasma samples were collected on days 3, 10, 17, and 5.5 months postpartum. On day 3, infant exposure via colostrum was low. On day 10 and 17, after steady-state exposure from exclusive breastfeeding, nadolol was detectable in the infant at very low concentrations, below the neonatal therapeutic range and 10-fold lower than maternal levels. By 5.5 months, during mixed feeding, nadolol in the infant was undetectable. No adverse effects were observed. This is the first report of paired maternal–infant nadolol plasma concentrations with extended follow-up. Despite pharmacokinetic concerns, infant systemic exposure was minimal even during exclusive breastfeeding. These findings support integrating maternal cardiovascular treatment with breastfeeding goals in a multidisciplinary care approach, though confirmation with additional cases is needed.

Original languageEnglish
Pages (from-to)3169-3171
Number of pages3
JournalPediatric Cardiology
Volume47
Issue number7
Early online date3 Dec 2025
DOIs
Publication statusPublished - Oct 2026

Keywords

  • Beta-blocker
  • Breastfeeding
  • Long QT syndrome
  • Nadolol
  • Neonatal safety
  • Pharmacovigilance

Fingerprint

Dive into the research topics of 'Breastfeeding During Maternal Nadolol Therapy for Long QT Syndrome: Five-Month Infant Follow-Up'. Together they form a unique fingerprint.

Cite this